OSE Immunotherapeutics Strengthens Leadership and Executive
Committee
OSE Immunotherapeutics Strengthens
Leadership and Executive Committee
NANTES, France, December 2, 2024 –
6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE), today announced that it has strengthened the
company’s leadership and executive team with two new appointments.
Fiona Olivier has been appointed Chief Corporate
Affairs and Investor Relations Officer and has joined the Executive
Committee of OSE Immunotherapeutics. Aurore
Morello, Head of Research and Director of R&D Programs
will also now serve on the Executive Committee. Both report
directly to Nicolas Poirier, CEO. Their appointments are effective
immediately.
Dominique Costantini,
co-founder, Director of Development and Strategy and former CEO and
Chairman of the Board will retire by the end of 2024. Dominique has
been an integral part of OSE Immunotherapeutics from its inception,
contributing significantly to the company strategy and portfolio
development.
Fiona Olivier joins the company
in the newly created position of Chief Corporate Affairs and
Investor Relations Officer. Fiona will contribute to the corporate
evolution of the company in close collaboration with the CEO and
will be responsible for shaping and communicating the company’s
strategic vision to stakeholders, managing investor relations,
overseeing corporate communications to enhance the company’s public
image and ensuring alignment with the strategic goals.
Newly appointed to the Executive Committee,
Aurore Morello, Head of Research and Director of
R&D Programs will also contribute to shaping the company’s
strategic direction, driving scientific discovery and technological
advancements to support OSE Immunotherapeutics’ mission of
delivering cutting-edge immunotherapeutic solutions.
Speaking about the evolution in the Executive
Committee, Nicolas
Poirier, Chief Executive
Officer, OSE Immunotherapeutics says: “Dominique has been an
emblematic leader at OSE Immunotherapeutics for the past 12 years.
Since co-founding the company, she has been instrumental in every
step the company has taken in terms of strategy and development.
Many of us have benefited from Dominique’s mentorship and guidance
over the years and we have grown stronger as a result. On behalf of
the Board, our leadership team and our employees, I extend my
heartfelt thanks to Dominique and wish her happiness and fulfilment
in her retirement.
“As we continue to strengthen our Executive
Committee, I am thrilled to have Fiona and Aurore join the team at
this remarkable turning point in our history. Fiona is a seasoned
expert in communications and public affairs in large pharma
companies and brings to OSE a wealth of experience across multiple
therapeutic areas. Her international experience, coupled with her
business acumen, her focus on patients and other external
stakeholders as well as her ability to engage teams, will be of
great value as we continue to position OSE Immunotherapeutics as a
European biotechnology champion built on scientific excellence and
collaboration.
“Like many of our researchers, Aurore excels
in mastering the various technological building blocks that enable
the design of tailored drugs, ultimately delivering novel biology
for the benefit of patients. Over the last two years, Aurore’s
scientific excellence and her leadership have been instrumental in
advancing our company’s pre-clinical pipeline. Having worked with
Aurore for the past ten years, I am very proud to see her take on
this new responsibility. She is a shining example of our internal
talent that continues to grow and develop in parallel with the
company.”
Fiona Olivier, Chief Corporate
Affairs and Investor Relations Officer, OSE Immunotherapeutics
Fiona joins OSE Immunotherapeutics from Sanofi,
where she served as Global Head of Corporate Affairs for the
General Medicines division since 2021. In this role, she oversaw
communications for a major transformation and modernization effort.
She led corporate affairs activities for the acquisition and
integration of two immunology-focused biotech companies and
spearheaded efforts to shape the market for global product
launches. Fiona has 30-years international experience in
communications, public affairs, and patient engagement at leading
global companies such as AbbVie, Abbott, and GSK. Additionally, she
has worked as a consultant at Ketchum, a global communications firm
(Omnicom company), serving clients across multiple sectors and
geographies.
Fiona’s career has taken her from Ireland to
Poland and the UK before arriving in France in 1997. She holds a
degree in communications from Dublin City University, and a
master’s in public Affairs and Public Policy from Sciences Po
Paris.
"After years of engaging with the biotech
sector through various partnerships, I am thrilled to fully immerse
myself in this dynamic innovation ecosystem. The exchanges with our
talented scientists and engineers are already inspiring, as I
witness firsthand the genesis of future therapies and technologies.
Collaborating with the development teams to bring potential
treatments closer to the patients who need them is also
particularly rewarding.
I have always been a strong advocate for a
robust French and European life sciences sector. In my new role at
OSE Immunotherapeutics, I am committed to building a sustainable
European champion, driving innovation and excellence in
healthcare," Fiona Olivier.
Aurore
Morello, Head of Research and
Director of R&D Programs
Aurore joins the Executive Committee and takes
on additional responsibilities in leadership and strategy, having
been appointed Head of Research and Director of R&D Programs
for OSE Immunotherapeutics in 2022.
She joined the company in 2016 from the Memorial
Sloan Kettering Cancer Center in New York where she worked in the
field of engineered CAR-T cell therapy. Prior to that, Aurore was
focused on designing and improving novel targeted immunotherapy
that are able to specifically induce apoptosis of cancer cells at
the French National Center for Scientific Research
(CNRS).
Aurore has been instrumental in driving OSE
Immunotherapeutics’ research efforts, such as exploring and
translating immunological discoveries into potential drug
candidates, which have either joined the company’s development
pipeline or that of its pharmaceutical partners. Her extensive
background in immunology and technology, combined with her
innovative mindset, will be invaluable as OSE Immunotherapeutics
continues its mission of advancing best in class science.
Aurore holds a bachelor’s degree in Cellular
Biology and Genetics, and a master’s degree in Molecular Biology,
with a specialization in Immunology and Cellular Communication,
both from the University of Rennes. She earned her PhD in
Immunology and Cancer from the University of Bordeaux.
“I am incredibly honored to join the
Executive Team at OSE Immunotherapeutics. Having grown within this
remarkable company, I have witnessed firsthand our relentless
pursuit of innovation and excellence. This new responsibility
allows me to further contribute to our mission of developing
groundbreaking therapies that can transform patients’ lives. I look
forward to continuing to lead our talented research teams and
driving forward our ambitious R&D programs, ensuring we persist
in pushing the boundaries of science and healthcare,”
Aurore Morello.
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company
dedicated to developing first-in-class assets in immuno-oncology
(IO) and immuno-inflammation (I&I) that address the unmet
patient needs of today and tomorrow. We partner with leading
academic institutions and biopharmaceutical companies in our
efforts to develop and bring to the market transformative medicines
for people with serious diseases. OSE Immunotherapeutics is based
between Nantes and Paris and is quoted on Euronext.
Additional information about OSE
Immunotherapeutics assets is available on the Company’s website:
www.ose-immuno.com. Follow us on X and LinkedIn
Contacts
Fiona
Olivier
fiona.olivier@ose-immuno.com
Sylvie Détry
sylvie.detry@ose-immuno.com
|
French
Media Contact
FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact
Rooney Partners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
|
|
Forward-looking statements
This press release contains express or implied information and
statements that might be deemed forward-looking information and
statements in respect of OSE Immunotherapeutics. They do not
constitute historical facts. These information and statements
include financial projections that are based upon certain
assumptions and assessments made by OSE Immunotherapeutics’
management considering its experience and its perception of
historical trends, current economic and industry conditions,
expected future developments and other factors they believe to be
appropriate.
These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on April 30, 2024, including the annual financial
report for the fiscal year 2023, available on the OSE
Immunotherapeutics’ website. Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date
hereof and does not undertake any obligation to update or revise
the forward-looking information or statements.
Ose Immunotherapeutics (LSE:0RAD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Ose Immunotherapeutics (LSE:0RAD)
Historical Stock Chart
From Dec 2023 to Dec 2024